Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.
复制标题
DOI:
10.1038/nn.3480
复制
发表时间:
2013-09
影响因子:
25
通讯作者:
Patel, Sachin
中科院分区:
文献类型:
--
作者:
Hermanson, Daniel J.;Hartley, Nolan D.;Gamble-George, Joyonna;Brown, Naoko;Shonesy, Brian C.;Kingsley, Phillip J.;Colbran, Roger J.;Reese, Jeffrey;Marnett, Lawrence J.;Patel, Sachin
Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatment of affective disorders. Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid to form prostaglandins, but also inactivates eCBs in vitro. However, the viability of COX-2 as a therapeutic target for in vivo eCB augmentation has not been explored. Here we utilized medicinal chemistry and in vivo analytical and behavioral pharmacological approaches to demonstrate a key role for COX-2 in the regulation of endocannabinoid (eCB) levels in vivo. A novel pharmacological strategy involving “substrate-selective” inhibition of COX-2 was used to augment eCB signaling without affecting related non-eCB lipids or prostaglandin synthesis. Behaviorally, substrate-selective inhibition of COX-2reducedanxiety-like behaviors in mice via increasede CB signaling. These data elucidate a key role for COX-2 in the regulation of eCB signaling and suggest substrate-selective pharmacology represents a viable approach for eCB augmentation with broad therapeutic potential.
登录
查看更多内容
DOI:
10.1073/pnas.97.2.925
发表时间:
2000-01-18
影响因子:
11.1
作者:
Kalgutkar, AS;Crews, BC;Marnett, LJ
通讯作者:
Marnett, LJ
影响因子:
4.5
作者:
Hohmann, Andrea G.;Suplita, Richard L., II
通讯作者:
Suplita, Richard L., II
影响因子:
5.9
作者:
Kunos, George
通讯作者:
Kunos, George
影响因子:
3.6
作者:
Kinsey, Steven G.;O'Neal, Scott T.;Long, Jonathan Z.;Cravatt, Benjamin F.;Lichtman, Aron H.
通讯作者:
Lichtman, Aron H.
影响因子:
--
作者:
Blankman, Jacqueline L.;Simon, Gabriel M.;Cravatt, Benjamin F.
通讯作者:
Cravatt, Benjamin F.